Cargando…

Rationale and design of the B-PROOF study, a randomized controlled trial on the effect of supplemental intake of vitamin B(12 )and folic acid on fracture incidence

BACKGROUND: Osteoporosis is a major health problem, and the economic burden is expected to rise due to an increase in life expectancy throughout the world. Current observational evidence suggests that an elevated homocysteine concentration and poor vitamin B(12 )and folate status are associated with...

Descripción completa

Detalles Bibliográficos
Autores principales: van Wijngaarden, Janneke P, Dhonukshe-Rutten, Rosalie AM, van Schoor, Natasja M, van der Velde, Nathalie, Swart, Karin MA, Enneman, Anke W, van Dijk, Suzanne C, Brouwer-Brolsma, Elske M, Zillikens, M Carola, van Meurs, Joyce BJ, Brug, Johannes, Uitterlinden, André G, Lips, Paul, de Groot, Lisette CPGM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3266639/
https://www.ncbi.nlm.nih.gov/pubmed/22136481
http://dx.doi.org/10.1186/1471-2318-11-80
Descripción
Sumario:BACKGROUND: Osteoporosis is a major health problem, and the economic burden is expected to rise due to an increase in life expectancy throughout the world. Current observational evidence suggests that an elevated homocysteine concentration and poor vitamin B(12 )and folate status are associated with an increased fracture risk. As vitamin B(12 )and folate intake and status play a large role in homocysteine metabolism, it is hypothesized that supplementation with these B-vitamins will reduce fracture incidence in elderly people with an elevated homocysteine concentration. METHODS/DESIGN: The B-PROOF (B-Vitamins for the PRevention Of Osteoporotic Fractures) study is a randomized double-blind placebo-controlled trial. The intervention comprises a period of two years, and includes 2919 subjects, aged 65 years and older, independently living or institutionalized, with an elevated homocysteine concentration (≥ 12 μmol/L). One group receives daily a tablet with 500 μg vitamin B(12 )and 400 μg folic acid and the other group receives a placebo tablet. In both tablets 15 μg (600 IU) vitamin D is included. The primary outcome of the study is osteoporotic fractures. Measurements are performed at baseline and after two years and cover bone health i.e. bone mineral density and bone turnover markers, physical performance and physical activity including falls, nutritional intake and status, cognitive function, depression, genetics and quality of life. This large multi-center project is carried out by a consortium from the Erasmus MC (Rotterdam, the Netherlands), VUmc (Amsterdam, the Netherlands) and Wageningen University, (Wageningen, the Netherlands), the latter acting as coordinator. DISCUSSION: To our best knowledge, the B-PROOF study is the first intervention study in which the effect of vitamin B(12 )and folic acid supplementation on osteoporotic fractures is studied in a general elderly population. We expect the first longitudinal results of the B-PROOF intervention in the second semester of 2013. The results of this intervention will provide evidence on the efficacy of vitamin B(12 )and folate supplementation in the prevention of osteoporotic fractures. TRIAL REGISTRATION: The B-PROOF study is registered with the Netherlands Trial (NTR NTR1333) and with ClinicalTrials.gov (NCT00696514).